Epilepsy and Seizure Medication
  Novartis Pharma US

 





MONOTHERAPY is a realistic goal - See results from a study showing that more patients achieved seizure control with their first antiepileptic drug monotherapy than with their second monotherapy. Go

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

Adult Efficacy

For your adult patients, the goal is monotherapy control


TRILEPTAL monotherapy continued partial seizure reduction for up to 3 years in an open-label extended study period

Reduction in frequency of partial seizures in an open-label extension phase1

Graph - Reduction in partial seizure frequency over 3 years

 Woman with Headphones
Adult Efficacy
Pediatric Efficacy
First-line Use
TRILEPTAL vs CBZ
Three-year, open-label extension phase of a multicenter, randomized, double-blind, controlled clinical trial of 287 patients (n=68 intent-to-treat TRILEPTAL patients aged 16 to 63 years; 62 patients started on TRILEPTAL monotherapy in the open-label extension phase).1,2

92% of patients experienced ≥50% reduction in frequency of partial seizures over 3 years1

NEXT: See data from monotherapy conversion trials

References:
1. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.



E-mail this page  | Print this page




TRILEPTAL Home  |  Professionals Main Page  |  Efficacy
Safety and Tolerability  |  Dosing  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us  |  Sitemap

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008 Novartis Pharmaceuticals Corporation. All rights reserved.